Frehemgo (denecimig)

Where it stands

Frehemgo (denecimig), from Novo Nordisk A/S, received a CHMP positive opinion on 17 September 2026. The record status is "Opinion", and no approval date is recorded. The product is therefore not yet authorised in the EU on the basis of these records.

The indication in the record is prophylaxis of bleeding episodes in patients with haemophilia A. The records give no further detail on age groups, haemophilia severity, inhibitor status or dosing, so the final scope of the label cannot be assessed from this data.

A CHMP opinion is a scientific recommendation to the European Commission, not a marketing authorisation. The Commission decision is what makes the product legally marketable across the EU.

Regulatory pathway and designations

No designations are recorded for this product. The records do not say whether it was assessed under accelerated assessment, or whether the opinion is for a standard, conditional or exceptional-circumstances authorisation. Any statement on those points would go beyond the data.

The next step is the Commission decision. The records give an expected date of 23 November 2026, calculated as the CHMP opinion date plus 67 days, the standard Commission decision period. This is an estimate and not an official date. The actual decision could fall earlier or later.

The only official milestone on record is the CHMP positive opinion of 17 September 2026.

Safety and pharmacovigilance

The records contain no safety data, risk management plan details, contraindications, warnings or post-authorisation commitments for Frehemgo. No conclusions on its safety profile can be drawn from them.

As general EU practice, a newly authorised medicine is covered by a risk management plan and routine pharmacovigilance, and the CHMP opinion is accompanied by product information (SmPC) and an assessment report. Whether additional monitoring or additional risk-minimisation measures apply to this product is not stated in the records.

What to watch

The main event is the European Commission decision, estimated for around 23 November 2026. Confirmation of the actual decision date, and whether the authorisation matches the CHMP-recommended indication, will be the key checkpoints.

Once published, the CHMP summary of opinion and the product information should show the precise indication wording, any conditions or obligations, and the safety section. These documents are not part of the current records.

Launch timing, pricing, reimbursement and competitive positioning are not covered by the records and are not addressed here.